Phase 2
Completed N=100
Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)
Source: ClinicalTrials.gov NCT05319860 ↗Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcomePrimary: Acute and Delayed Chemotherapy-Induced Nausea. The Self-reported Instruments Are Documented After the Chemotherapy Sessions and Collected on Study Visits 1, 2, and 3. — 5.35; 4.57; 5.20; 4.55 score on a scale
Summary
The purpose of this study is to evaluate the use of aromatherapy to reduce nausea, vomiting, and the use of anti-emetic in cancer survivors undergoing moderate to highly emetogenic chemotherapy regimens.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Acute and Delayed Chemotherapy-Induced Nausea. The Self-reported Instruments Are Documented After the Chemotherapy Sessions and Collected on Study Visits 1, 2, and 3. |
5.35; 4.57; 5.20; 4.55 | — |
| PRIMARY Acute and Delayed Chemotherapy-Induced Vomiting. The Self-reported Instruments Are Documented After the Chemotherapy Sessions and Collected on Study Visits 1, 2, and 3. |
11.1; 7.77; 11.83; 5.95 | — |
| SECONDARY Change in Frequency of Antiemetic Medication Usage. The Self-reported Instruments Are Documented After the Chemotherapy Sessions and Collected on Study Visits 1, 2, and 3. |
9.89; 3.06 | — |
Eligibility Criteria
Inclusion Criteria
- 18 years of age or older
- Able to read and speak English or Spanish
- Able to and willing to give informed consent
- Currently undergoing moderate and high emetogenic chemotherapy (adjuvant or neoadjuvant)
- Receiving three or more remaining cycles of chemotherapy
- Symptoms of nausea or vomiting after the first chemotherapy infusion
Exclusion Criteria
- Unable or unwilling to give informed consent
- Sensitivity to essential oils*
- Olfactory disorders
- Receiving chemotherapy for the first time
- Undergoing low emetogenic chemotherapy regimens
- Patients with hormone-sensitive cancers
- Timely request of treating provider
Data sourced from ClinicalTrials.gov (NCT05319860). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.